Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib,
pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line
treatment in patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma,
nasal type.